These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cost-utility analysis of a pharmacotherapy follow-up for elderly nursing home residents in Spain.
    Author: Jódar-Sánchez F, Martín JJ, López del Amo MP, García L, Araújo-Santos JM, Epstein D.
    Journal: J Am Geriatr Soc; 2014 Jul; 62(7):1272-80. PubMed ID: 24891096.
    Abstract:
    OBJECTIVES: To compare the cost-effectiveness of a pharmacotherapy follow-up for elderly nursing home (NH) residents with that of usual care. DESIGN: Prospective observational study with a concurrent control group conducted over 12 months. SETTING: Fifteen NHs in Andalusia assigned to control (n = 6) or intervention (n = 9). PARTICIPANTS: Residents aged 65 and older. INTERVENTION: Pharmacotherapy follow-up. MEASUREMENTS: Negative outcomes associated with medication, health-related quality of life, cost, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER). ICERs were estimated for three scenarios: unadjusted cost per QALY (first scenario), costs adjusted for baseline prescribed medication and QALYs adjusted for baseline utility score (second scenario), and costs and QALYs adjusted for a fuller set of baseline characteristics (third scenario). RESULTS: Three hundred thirty-two elderly residents were enrolled: 122 in the control group and 210 in the intervention group. The general practitioner accepted 88.7% (274/309) of pharmacist recommendations. Pharmacist interventions reduced the average number of prescribed medication by 0.47 drugs (P < .001), whereas the average prescribed medication increased by 0.94 drugs in the control group (P < .001). Both groups reported a lower average EuroQol-5D utility score after 12 months (intervention, -0.0576, P = .002; control, -0.0999, P = .003). For the first scenario, usual care dominated pharmacotherapy follow-up (was less effective and more expensive). Adjusted ICERs were € 3,899/QALY ($5,002/QALY) for the second scenario and € 6,574/QALY ($8,433/QALY) for the third scenario. For a willingness to pay of € 30,000/QALY ($38,487/QALY), the probabilities of the pharmacotherapy follow-up being cost-effective were 35% for the first scenario, 78% for the second, and 76% for the third. CONCLUSION: Pharmacotherapy follow-up is considered cost-effective for elderly NH residents in Spain.
    [Abstract] [Full Text] [Related] [New Search]